Every 8-K that RxSight, Inc. (RXST) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow RXST and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RXST filings page.
RxSight, Inc. reported second-quarter 2026 revenue of $33.7 million, including $6.5 million from its strategic collaboration with Alcon and $27.2 million of product sales. Product sales declined 19% from a year earlier, reflecting competitive trialing and softer consumer sentiment, and included 24,917 Light Adjustable Lens units and 12 Light Delivery Devices.
Excluding collaboration revenue, gross margin was 71.2% versus 74.9% a year ago; including it, gross margin was 76.7%. Operating expenses were $39.7 million, and the company posted a net loss of $12.1 million, or $0.29 per share, with adjusted net loss of $4.6 million, or $0.11 per share. Cash, cash equivalents and short-term investments totaled $208.8 million as of June 30, 2026.
RxSight appointed Aziz Mottiwala as President and Chief Executive Officer, entered a strategic collaboration with Alcon featuring up to $200 million in potential upfront and milestone payments plus future royalties, and advanced next-generation Light Adjustable Lens technologies. In connection with the leadership transition, it withdrew 2026 guidance and plans to resume formal guidance in early 2027.
RxSight, Inc. announced a planned leadership transition effective July 20, 2026, appointing Aziz Mottiwala as President and Chief Executive Officer and a Class II director, while long-time CEO Ron Kurtz, M.D. becomes Chief Medical Officer and resigns from the board.
Mottiwala’s employment letter provides a $750,000 base salary, an annual bonus opportunity of up to 90% of base, a guaranteed $337,500 cash bonus for 2026, and new-hire equity awards valued at $14,000,000, split between stock options and RSUs with multi‑year vesting. A Change in Control Severance Agreement includes cash severance equal to 18 months of salary and target bonus, COBRA reimbursements and 100% equity vesting acceleration upon specified terminations and upon a change in control.
A transition agreement keeps Kurtz at a $740,000 base salary with up to 100% target bonus, four retention bonuses of $370,000 each, and 500,000 RSUs vesting through 2028, plus revised severance protections. The board also adopted a 2026 Inducement Equity Incentive Plan reserving 3,500,000 shares for new‑hire awards. Previously communicated financial guidance remains unchanged.
RxSight, Inc. announced preliminary second quarter 2026 results and updated its 2026 outlook following a strategic collaboration with Alcon. Q2 2026 total revenue is expected at $32 to $34 million, including $5 to $7 million from the Alcon collaboration. Product sales were about $27 million, driven by 24,917 Light Adjustable Lens units and 11 Light Delivery Devices, plus one rental placement. The company reported $209 million in cash, cash equivalents and short-term investments as of June 30, 2026. For full-year 2026, total revenue is guided to $140 to $160 million, with sales of $110 to $120 million, below prior sales guidance, and collaboration revenue of $30 to $40 million. RxSight now expects gross margin of 73% to 75%, above previous guidance, and operating expenses near the high end of $150 to $160 million, as it accelerates commercial and R&D investments.
RxSight, Inc. entered into a significant license, collaboration and development agreement with Alcon to co-develop and commercialize light-adjustable presbyopia-correcting intraocular lenses that combine RxSight’s Light Adjustable Technology with Alcon’s existing optics.
Alcon will pay RxSight a $60 million upfront cash payment, with an optional $70 million feasibility milestone if Alcon chooses to continue after early technical criteria are met. If the collaboration proceeds, Alcon would also pay a $30 million milestone upon first FDA submission and an optional $40 million approval milestone upon U.S. regulatory approval of the first product, plus ongoing 30% royalties on net sales of collaboration products, subject to minimums and adjustments.
RxSight will prioritize development, seek U.S. regulatory approvals and exclusively manufacture and supply the collaboration lenses, while Alcon will lead commercialization and has rights to terminate by declining key milestone payments. The agreement generally runs for ten years after first product approval, with renewal options and multiple termination and reversion provisions.
RxSight, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 16, 2026. Of 41,396,609 common shares outstanding as of April 21, 2026, 33,299,192 were represented, about 80.4% of shares entitled to vote.
Stockholders re-elected three Class II directors — William J. Link, Robert Warner, and Shweta Singh Maniar — to serve until the 2029 annual meeting and until their successors are elected and qualified.
They also approved, on an advisory basis, executive compensation, with 21,236,615 votes for and 2,742,189 against, and ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 33,062,585 votes for and 92,653 against.
RxSight, Inc. reported first quarter 2026 sales of $30.9 million, down 18.5% from a year earlier, mainly due to lower Light Delivery Device volumes, while Light Adjustable Lens procedures decreased 0.4% year over year. Gross profit margin improved to 76.1% from 74.8% on a richer lens mix.
Total operating expenses rose to $41.3 million from $39.0 million as the company expanded its global commercial and support teams. Net loss widened to $15.9 million, or $0.38 per share, versus $8.2 million, or $0.20 per share, with adjusted net loss at $7.9 million, or $0.19 per share. Cash, cash equivalents and short-term investments totaled $217.9 million as of March 31, 2026. RxSight reiterated 2026 revenue guidance of $120 to $135 million and gross margin guidance of 70% to 72%, and now expects operating expenses at the high end of its prior $150 to $160 million range.
RxSight, Inc. filed an amended report to update details about the compensation of its new Chief Financial Officer, Mark Wilterding. The company confirms that, under his employment agreement effective January 11, 2026, his cash sign-on bonus was set at $169,348.10 and paid on March 13, 2026, after payroll deductions and required withholding.
The amendment also corrects the vesting schedule for his stock option. 25% of the shares underlying the option will vest on the first anniversary of January 11, 2026, and the remaining shares will vest in equal monthly installments over the following three years, so that all option shares are fully vested four years from that date, subject to his continued employment and the terms of the option agreement. All other aspects of the original report remain unchanged.
RxSight, Inc. reported mixed fourth quarter and full-year 2025 results, highlighted by strong adoption of its Light Adjustable Lens (LAL) but weaker Light Delivery Device (LDD) sales. Full-year revenue was $134.5 million, down 4% from 2024, as 12% LAL growth was offset by a 48% drop in LDD system sales.
Gross profit for 2025 rose to $103.0 million, with margin improving to 76.6% from 70.7%, driven by a higher mix of LAL revenue. Operating expenses increased 11% to $151.2 million, reflecting commercial expansion, R&D and marketing, leading to a wider net loss of $38.9 million, or $(0.95) per share. Adjusted net loss was $7.3 million, or $(0.18) per share.
In Q4 2025, revenue was $32.6 million, down 19% year over year, with LAL revenue down 1% and LDD revenue down 72% after record placements in the prior year quarter. Q4 gross margin improved to 77.5%, while net loss was $9.2 million. The company ended 2025 with $228.1 million in cash, cash equivalents and short-term investments and an installed base of 1,134 LDDs supporting 109,615 LAL units sold in 2025.
For 2026, RxSight guided to revenue of $120.0–$135.0 million, gross margin of 70%–72%, operating expenses of $150.0–$160.0 million, and non-cash stock-based compensation of $30.0–$32.0 million, reflecting expectations for lower LDD placements and higher per-unit manufacturing costs.
RxSight, Inc. filed an 8-K to report two main updates. The company issued a press release with preliminary, unaudited financial and operational results for the fourth quarter and full year 2025, furnished as Exhibit 99.1 and not treated as filed for liability purposes.
The board appointed Mark Wilterding as Chief Financial Officer and principal financial and accounting officer, effective January 11, 2026, succeeding Shelley Thunen. His employment terms include a $550,000 annual base salary, an annual bonus opportunity of up to 65% of base salary, and equity grants consisting of an option to purchase 258,770 shares and 163,528 restricted stock units with four-year vesting schedules, all under the 2021 Equity Incentive Plan. He also entered into change in control severance and indemnification agreements consistent with other executive officers.
RxSight, Inc. reported that it has entered into a transition agreement and release of claims, as well as a consulting agreement, with its outgoing Chief Financial Officer and principal financial and accounting officer, Shelley Thunen. Under these agreements, she will provide certain transition services to support the company after her employment separation date.
The company stated that this Chief Financial Officer leadership transition does not affect its outlook or expectations for full-year 2025. RxSight also noted that it continues to execute on its strategic and operational priorities, indicating that its business plans and financial expectations remain intact despite the change in its finance leadership.
RxSight, Inc. (RXST) furnished quarterly results via a current report. The company announced results of operations and financial condition for the three and nine months ended September 30, 2025, under Item 2.02. The information was furnished, not filed, meaning it is not subject to Section 18 liability and is not incorporated into other filings unless specifically referenced. A press release with the details is included as Exhibit 99.1, with the cover page interactive data tagged as Exhibit 104.
RxSight, Inc. filed an amendment to update a prior report about the appointment of Raymond W. Cohen to its Board of Directors. The new filing explains that, on August 14, 2025, the board appointed Cohen to both the Compensation Committee and the Audit Committee, effective immediately.
After these changes, the Compensation Committee consists of Robert J. Palmisano (Chair), J. Andy Corley, Robert Warner, and Raymond W. Cohen. The Audit Committee consists of Julie B. Andrews (Chair), Juliet Tammenoms Bakker, Tamara R. Fountain, M.D., and Raymond W. Cohen.